Skip to main content
. Author manuscript; available in PMC: 2023 Mar 25.
Published in final edited form as: Gynecol Oncol. 2020 Dec 13;160(2):568–578. doi: 10.1016/j.ygyno.2020.12.004

Figure 4.

Figure 4.

Validation of SMARCA4 mutation by Sanger sequencing in COV434 cell line and original tumor sample, and in TOV-112D cell line. DNA samples were extracted from both cell lines and the COV434 primary tumour, and Sanger Sequencing was performed. A. COV434 sequencing using primers that amplified the splice site (chr19:11145589) of SMARCA4 gene. The red rectangle denotes the identical mutation in COV434 cells and the original tumor sample compared to a reference sample. B. TOV-112D sequencing using primers that amplified regions around the chr19: 11145589 site of SMARCA4 gene.